View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 18, 2021updated 12 Jul 2022 11:06am

Monash University’s new antibiotic against superbugs starts US trial

No new polymyxins were approved after polymyxin B and colistin launched in the late 1950s.

Researchers at Monash University in Australia have announced a Phase I clinical trial of a new antibiotic, QPX9003, to treat infections by antibiotic-resistant bacteria or superbugs in the US.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

US-based biopharmaceutical firm Qpex Biopharma has commenced the study. Qpex and Monash University team worked together to advance the antibiotic into clinical development.

Monash Institute of Pharmaceutical Sciences (MIPS) and the Monash Biomedicine Discovery Institute (BDI) discovered QPX9003.

The drug is an intravenous synthetic next-generation polymyxin developed to treat Gram-negative superbug infections.

According to the researchers, no new polymyxins received approval after polymyxin B and colistin were launched in the late 1950s.

Gram-negative bacteria, considered a global health emergency, can lead to serious infections such as pneumonia, bloodstream infections, urinary tract infections, and meningitis.

Bacterial superbugs can cause ten million deaths annually by 2050 if no new antibiotics are available for treatment, the team noted citing the World Health Organization.

Monash University antibiotic drug discovery programme head professor Jian Li said: “QPX9003 shows significantly improved safety and efficacy over the currently used polymyxin antibiotics in pre-clinical studies, in particular for lung infections.”

The Phase I trial by Qpex Biopharma will assess the safety, tolerability and pharmacokinetics of intravenous QPX9003 in healthy adults.

It is being carried out under a US investigational new drug as part of the company’s alliance with the Biomedical Advanced Research and Development Authority (BARDA).

Qpex Biopharma president and CEO Dr Michael Dudley said: “We believe the clinical candidate QPX9003 emerging from this collaboration with internationally leading scientists in polymyxin research will be the best in this class.

“This programme addresses the serious and urgent global antibiotic resistance threats in a timely manner.”

In addition to QPX9003, the company exclusively licenced global rights to other synthetic polymyxin antibiotics discovered by Monash.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena